Phytochemicals in the Management of Chronic Inflammatory Diseases

Wei Jian Chen [1*], Li Mei Liu [2], Hao Ming Wang [3], Xin Yu Zhang [4]
[1] School of Pharmaceutical Sciences, Peking University, China
[2] Institute of Nano Drug Delivery, Fudan University, China
[3] Department of Oncology Nanotherapeutics, Shanghai Jiao Tong University, China
[4] National Center for Nanoscience and Technology, Beijing, China

* Corresponding Author: **Wei Jian Chen**

Article Info

ISSN (online): 3107-393X
Volume: 06
Issue: 04
July-August 2025
Received: 09-06-2025
Accepted: 11-07-2025
Published: 12-08-2025
Page No: 34-40

Abstract
Chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, type 2 diabetes mellitus, cardiovascular disease, and neurodegenerative disorders, represent a formidable global health challenge, collectively affecting hundreds of millions of individuals and imposing substantial socioeconomic burdens on healthcare systems worldwide. Conventional pharmacological approaches, including nonsteroidal anti-inflammatory drugs, corticosteroids, and biologic agents, although clinically effective in the short term, are associated with significant adverse effects, high treatment costs, and limitations in long-term safety profiles, necessitating the exploration of safer, cost-effective, and mechanistically diverse therapeutic alternatives. This review critically examines the role of phytochemicals, bioactive plant-derived compounds encompassing flavonoids, polyphenols, alkaloids, and terpenoids, as promising candidates for the management of chronic inflammatory diseases. We evaluate the molecular and cellular mechanisms through which these compounds modulate key inflammatory pathways, including the nuclear factor kappa B (NF-kB) signalling cascade, the mitogen-activated protein kinase (MAPK) pathway, the NLRP3 inflammasome, and JAK-STAT signalling, alongside their capacity to suppress proinflammatory cytokine expression, reduce oxidative stress, and restore immune homeostasis. Preclinical evidence from in vitro and *in vivo* models is systematically discussed alongside emerging clinical data. Challenges in bioavailability, standardization, pharmacokinetic variability, and regulatory compliance are addressed in the context of novel drug delivery strategies, including nanoparticulate formulations and lipid-based carriers. This review underscores the translational relevance of phytochemicals and advocates for rigorous, well-designed clinical trials to substantiate their therapeutic integration into mainstream anti-inflammatory medicine.

Keywords: Phytochemicals, Chronic inflammation, Anti-inflammatory agents, Natural products, Translational medicine, Therapeutics

1. Introduction

Chronic inflammation is a sustained, dysregulated immune response that underlies the pathophysiology of numerous prevalent non-communicable diseases. Unlike acute inflammation, which is a protective, self-resolving response to tissue injury or infection, chronic inflammation persists over months to years, perpetuating tissue damage, organ dysfunction, and systemic metabolic disturbances [1]. The global burden of chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, atherosclerosis, and neuroinflammatory disorders, is staggering; the World Health Organization has identified non-communicable diseases rooted in chronic inflammation as the leading cause of

morbidity and mortality in the twenty-first century [2].

Current first-line pharmacological interventions, such as nonsteroidal anti-inflammatory drugs and corticosteroids, provide symptomatic relief but are associated with a range of dose-dependent adverse effects including gastrointestinal ulceration, immunosuppression, and adrenal insufficiency [3]. Biological agents targeting specific cytokines or immune receptors, including anti-tumour necrosis factor-alpha (TNF-alpha) biologics, have revolutionized the management of autoimmune diseases but remain prohibitively expensive and accessible only in high-income settings [4]. Furthermore, long-term biological therapy is associated with increased susceptibility to opportunistic infections and potential malignancy [5]. These limitations have intensified interest in naturally derived bioactive compounds as complementary or alternative therapeutic agents.

Phytochemicals constitute a structurally diverse class of secondary metabolites produced by plants, many of which exhibit potent anti-inflammatory, antioxidant, immunomodulatory, and cytoprotective activities [6]. Historically embedded in traditional medicine systems, including Ayurveda, Traditional Chinese Medicine, and African ethnobotany, phytochemicals have increasingly attracted scientific scrutiny as tools for drug discovery and therapeutic development. This review provides a comprehensive and critically evaluated synthesis of current evidence supporting the role of phytochemicals in managing chronic inflammatory diseases, with an emphasis on their molecular mechanisms, translational research findings, clinical applications, and future directions.

2. Biological Basis of Chronic Inflammation

The pathophysiological architecture of chronic inflammation involves the convergent dysregulation of innate and adaptive immune responses, resulting in a self-reinforcing cycle of immune cell activation, cytokine release, and tissue destruction. Central to this process is the persistent activation of macrophages, dendritic cells, and T lymphocytes, which maintain a proinflammatory microenvironment through the secretion of cytokines including interleukin-1 beta (IL-1beta), IL-6, IL-17, and tumour necrosis factor-alpha (TNF-alpha) [7].

At the molecular level, chronic inflammation is principally orchestrated by the nuclear factor kappa B (NF-kB) transcription factor family, which governs the expression of genes encoding proinflammatory cytokines, adhesion molecules, and inducible enzymes such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) [8]. Parallel activation of the MAPK pathway, particularly the p38 and c-Jun N-terminal kinase (JNK) branches, amplifies inflammatory gene transcription in response to stress signals and cytokine stimulation [9]. The NLRP3 inflammasome, a cytoplasmic multiprotein complex, plays a particularly significant role in sterile inflammation by activating caspase-1 and facilitating the maturation of IL-1beta and IL-18, connecting metabolic dysregulation to systemic inflammatory signalling [10].

Oxidative stress represents another critical dimension of chronic inflammation, with reactive oxygen species (ROS) generated by activated phagocytes not only directly damaging cellular components but also serving as second messengers that perpetuate NF-kB activation [11]. The interplay between oxidative stress and inflammatory signalling creates a pathological feedback loop that sustains tissue injury in diseases such as atherosclerosis, non-alcoholic steatohepatitis, and neurodegenerative conditions. Understanding these interconnected mechanisms is essential for identifying molecular targets amenable to phytochemical intervention.

3. Major Classes of Phytochemicals and Their Pharmacological Relevance

Phytochemicals represent a heterogeneous group of naturally occurring plant secondary metabolites, broadly categorized into flavonoids, polyphenols, alkaloids, terpenoids, and organosulfur compounds, each with distinct chemical structures and pharmacological profiles. Their evolutionary role in plant defence against pathogens, ultraviolet radiation, and herbivory has endowed them with biological activities relevant to human disease, particularly inflammation [12].

Flavonoids constitute one of the most extensively studied classes of phytochemicals and are ubiquitously distributed in fruits, vegetables, tea, and legumes. This class encompasses flavones, flavonols, flavanones, isoflavones, catechins, and anthocyanins, all sharing a common phenylchromane skeleton [13]. Notable members include quercetin, kaempferol, luteolin, and epigallocatechin gallate (EGCG), each demonstrating significant capacity to inhibit proinflammatory signalling cascades. Polyphenols, a broader category that includes flavonoids as well as stilbenes such as resveratrol and phenolic acids, are characterized by multiple hydroxyl groups attached to aromatic ring structures and exert potent antioxidant and anti-inflammatory effects through free radical scavenging and modulation of redox-sensitive transcription factors [14].

Alkaloids, nitrogenous compounds derived primarily from amino acid biosynthesis, include berberine, colchicine, and piperine. Berberine, isolated from Berberis species, has garnered particular attention for its capacity to activate AMP-activated protein kinase (AMPK) and suppress NF-kB-mediated inflammatory gene expression, making it relevant in metabolic and inflammatory disease contexts [15].

Terpenoids, the largest class of plant secondary metabolites, include monoterpenes, sesquiterpenes, diterpenes, and triterpenoids. Curcumin, a polyphenolic curcuminoid derived from Curcuma longa, and boswellic acids from Boswellia serrata represent well-characterized terpenoids with demonstrated inhibitory activity against 5-lipoxygenase (5-LOX) and NF-kB [16].

Table 1: Classification of Major Anti-Inflammatory Phytochemicals: Sources and Mechanisms of Action

Phytochemical Class	Representative Compounds	Natural Sources	Primary Mechanism of Action	Key Molecular Targets
Flavonoids	Quercetin, Luteolin, EGCG, Kaempferol	Onions, green tea, apples, kale	NF-kB inhibition, COX-2 suppression, antioxidant activity	NF-kB, AP-1, Nrf2, COX-2
Polyphenols / Stilbenes	Resveratrol, Curcumin, Ellagic acid	Grapes, turmeric, pomegranate	Inhibition of NF-kB, MAPK; Nrf2 activation; SIRT1 modulation	NF-kB, SIRT1, MAPK, Nrf2
Alkaloids	Berberine, Piperine, Colchicine	Barberry, black pepper, autumn crocus	AMPK activation; NF-kB and NLRP3 suppression; tubulin disruption	AMPK, NF-kB, NLRP3, tubulin
Triterpenoids	Boswellic acid, Ursolic acid, Oleanolic acid	Boswellia, rosemary, olive leaf	5-LOX inhibition; NF-kB suppression; HIF-1alpha modulation	5-LOX, NF-kB, HIF-1alpha
Organosulfur Compounds	Allicin, Sulforaphane, Diallyl disulfide	Garlic, broccoli, cruciferous vegetables	Nrf2-HO-1 pathway induction; iNOS and COX-2 inhibition	Nrf2, HO-1, iNOS, COX-2

4. Molecular and Cellular Mechanisms of Anti-Inflammatory Action

The anti-inflammatory efficacy of phytochemicals derives from their pleiotropic capacity to interfere with multiple nodal points within inflammatory signalling networks. The NF-kB pathway is among the most comprehensively characterized targets. Curcumin, quercetin, and resveratrol have each been demonstrated to inhibit IkB kinase (IKK) complex activity, thereby preventing phosphorylation and subsequent proteasomal degradation of inhibitory kappa B proteins (IkB), which normally sequester NF-kB in the cytoplasm [17]. By preserving IkB integrity, these phytochemicals prevent nuclear translocation of active NF-kB dimers and the transcriptional upregulation of genes encoding TNF-alpha, IL-6, IL-1beta, and other proinflammatory mediators [18].

The MAPK cascade, comprising the extracellular signal-regulated kinase (ERK), JNK, and p38 MAPK branches, constitutes another major target. Luteolin and EGCG suppress phosphorylation of p38 MAPK and JNK in activated macrophages, attenuating the downstream activation of activator protein 1 (AP-1) and subsequent cytokine gene transcription [19]. Phytochemical modulation of the NLRP3 inflammasome has emerged as an area of considerable research interest; berberine and quercetin have been shown to prevent assembly of the NLRP3 complex and suppress caspase-1 activation, thereby reducing IL-1beta and IL-18 maturation in models of metabolic inflammation [20].

Phytochemicals also modulate the Nrf2-Keap1 antioxidant signalling axis. Sulforaphane, an isothiocyanate derived from cruciferous vegetables, is among the most potent known activators of nuclear factor erythroid 2-related factor 2 (Nrf2), which drives expression of cytoprotective and antioxidant enzymes including haem oxygenase-1 (HO-1), glutathione S-transferase, and superoxide dismutase [21]. By reducing cellular redox burden, Nrf2 activation indirectly attenuates ROS-mediated NF-kB activation, thereby establishing a mechanistic link between antioxidant and anti-inflammatory activities. Additionally, resveratrol activates sirtuin-1 (SIRT1), a NAD+-dependent deacetylase that deacetylates and inactivates the p65 subunit of NF-kB, further illustrating the multilayered inhibitory strategies employed by phytochemicals [22].

At the cellular level, phytochemicals regulate the polarization of macrophages. Proinflammatory M1 macrophages, characterized by secretion of IL-12, TNF-alpha, and high levels of iNOS, have been shown to shift toward the anti-inflammatory M2 phenotype upon treatment with curcumin and resveratrol, promoting the release of IL-10 and transforming growth factor-beta (TGF-beta), which facilitate tissue repair and immune resolution [23].



Fig 1: Key inflammatory signalling pathways and molecular targets modulated by phytochemicals.

5. Preclinical Evidence and Translational Research

The preclinical evidence base supporting the anti-inflammatory potential of phytochemicals is extensive, encompassing a wide range of in vitro cellular models and *in vivo* animal studies conducted across diverse disease contexts. In vitro systems, including lipopolysaccharide (LPS)-stimulated macrophage lines such as RAW 264.7 and primary peritoneal macrophages, have provided mechanistic insights into cytokine suppression, enzyme inhibition, and transcription factor modulation by phytochemicals including curcumin, quercetin, and berberine [24]. These findings have been complemented by studies employing human monocyte-derived macrophages and ex vivo synovial tissue preparations, which offer greater translational fidelity.

Animal models of chronic inflammatory disease have corroborated in vitro observations. Collagen-induced arthritis, dextran sulfate sodium-induced colitis, and high-fat diet-induced metabolic inflammation models have demonstrated significant reductions in histopathological injury scores, synovial hyperplasia, and serum cytokine levels following administration of phytochemical extracts or purified compounds [25]. Crucially, the pharmacokinetic behaviour of phytochemicals *in vivo* reveals substantial challenges in translational applicability. Oral bioavailability of curcumin, for instance, is extremely limited due to poor aqueous solubility, rapid hepatic conjugation, and extensive gut wall metabolism, resulting in plasma concentrations far below those observed to be efficacious in cellular assays [26]. Similar limitations apply to quercetin and resveratrol, whose biological half-lives are shortened by extensive phase II biotransformation.

Several strategies have been explored in preclinical models to overcome these pharmacokinetic limitations. Piperine, derived from black pepper, has been employed as a bioavailability enhancer for curcumin, inhibiting its intestinal glucuronidation and increasing systemic exposure by up to twenty-fold [27]. Nanoparticulate encapsulation within polymeric, lipid-based, or micellar carriers has demonstrated marked improvements in the oral bioavailability and tissue distribution of poorly soluble phytochemicals in rodent models [28]. These advances are critical prerequisites for meaningful clinical translation.



Fig 2: Translational progression pipeline for phytochemical-based anti-inflammatory therapies.

6. Clinical Evidence, Bioavailability, and Safety Considerations

Clinical investigation of phytochemicals for chronic inflammatory diseases has expanded considerably over the past two decades, though the evidence base remains heterogeneous in quality, methodology, and study population. Curcumin has been the most extensively studied phytochemical in human trials. A systematic review and meta-analysis of randomized controlled trials evaluating curcumin supplementation in rheumatoid arthritis reported significant reductions in C-reactive protein (CRP) levels and Disease Activity Score-28 (DAS-28) in comparison with placebo groups, though the trials included were generally of short duration and modest sample size [29]. Similarly, clinical trials evaluating resveratrol in metabolic syndrome and type 2 diabetes have demonstrated improvements in inflammatory biomarkers including IL-6 and TNF-alpha, as well as modest reductions in fasting glucose and insulin resistance indices [30].

Despite these encouraging findings, significant methodological limitations constrain the interpretability of available clinical data. Heterogeneity in phytochemical formulation, dose, duration, and patient population across trials hampers direct comparison and meta-analytic synthesis. The absence of standardized extract preparations, reflecting variable phytochemical content between batches and suppliers, introduces substantial measurement error and reproducibility concerns [31]. Many trials lack adequate statistical power due to small sample sizes, and outcome measures frequently rely on surrogate biomarkers rather than validated clinical endpoints. The placebo response in inflammatory conditions is itself considerable, necessitating robust blinding and sham control strategies.

Bioavailability enhancement through advanced formulation technologies has demonstrated proof of concept in early-phase clinical studies. Theracurmin, a colloidal dispersion formulation of curcumin, achieved significantly higher plasma concentrations than native curcumin powder in healthy volunteers, supporting its use in exploratory clinical studies [32]. The safety profiles of commonly studied phytochemicals, including curcumin, quercetin, and berberine, are generally favourable at conventional dietary and supplemental doses; however, high-dose or prolonged administration warrants pharmacovigilance, particularly with regard to drug-phytochemical interactions mediated by

CYP450 enzyme inhibition or induction, which may alter the metabolism of co-administered therapeutics [33].

7. Technological and Formulation Advancements

The therapeutic translation of phytochemicals is fundamentally contingent on overcoming inherent physicochemical limitations, including poor water solubility, chemical instability under physiological conditions, and rapid metabolic inactivation. Advances in pharmaceutical nanotechnology have provided a spectrum of delivery platforms capable of addressing these challenges. Polymeric nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) have been extensively employed for encapsulation of curcumin and quercetin, conferring protection against premature degradation, sustained release characteristics, and enhanced cellular uptake through endocytotic pathways [34].

Lipid-based drug delivery systems, including solid lipid nanoparticles, nanostructured lipid carriers, and self-emulsifying drug delivery systems, exploit the affinity of hydrophobic phytochemicals for lipid matrices to enhance gastrointestinal absorption. Self-emulsifying formulations of curcumin have demonstrated up to forty-fold improvements in relative bioavailability compared with native compound in pharmacokinetic studies [35]. Cyclodextrin inclusion complexes offer an alternative approach, embedding hydrophobic phytochemicals within hydrophilic cyclodextrin cavities to increase aqueous solubility without compromising biological activity. Micellar and liposomal formulations, already established for conventional drugs, have been adapted for phytochemical delivery with promising preclinical outcomes.

Beyond oral delivery, intraarticular, transdermal, and inhaled administration routes are being explored for site-specific delivery of phytochemicals to inflamed tissues, circumventing first-pass metabolism and achieving locally efficacious concentrations with reduced systemic exposure [36]. Exosome-based delivery systems represent an emerging frontier, leveraging the natural cellular communication machinery to deliver phytochemicals with exquisite tissue targeting specificity. These technological advancements collectively represent a critical enabling infrastructure for the clinical advancement of phytochemical-based anti-inflammatory therapies.



Fig 3: Classification and botanical sources of major phytochemicals with anti-inflammatory properties.

8. Regulatory, Ethical, and Commercialization Challenges

The development of phytochemicals as approved therapeutic agents confronts a complex regulatory landscape that varies considerably across international jurisdictions. In the United States, phytochemicals are frequently marketed as dietary supplements under the Dietary Supplement Health and Education Act, which does not require demonstration of efficacy or equivalently rigorous safety standards as for pharmaceutical drugs [37]. In the European Union, the Traditional Herbal Medicinal Products Directive provides a pathway for registration of herbal medicinal products based on documented traditional use, but this route does not confer the same therapeutic claims permissible for approved drugs. The consequent regulatory ambiguity creates challenges for investment in rigorous clinical development programmes.

Intellectual property considerations present a further impediment to commercialization of naturally derived compounds. As phytochemicals are naturally occurring substances, they are generally not patentable in their native form, limiting the financial incentives for pharmaceutical companies to invest in large-scale clinical trials. Novel delivery formulations, specific extraction and purification methods, or newly identified synthetic derivatives of phytochemicals may be patentable, providing a potential avenue for intellectual property protection and associated commercial development [38]. Ethical considerations pertaining to the sustainable sourcing of botanicals, equitable benefit-sharing with indigenous communities whose traditional knowledge underpins ethnopharmacological leads, and environmental stewardship of plant resources must be integrated into the development framework for phytochemical-based medicines.

Quality control and standardization of phytochemical preparations represent critical technical challenges. The chemical composition of botanical extracts is subject to variation due to agronomic factors, geographical provenance, harvesting conditions, and processing methods. Without stringent standardization of active phytochemical content, inter-batch variability undermines the reliability of clinical trial outcomes and regulatory submissions [39]. International collaboration between regulatory agencies, academic researchers, and the herbal medicine industry is essential to develop harmonized standards for phytochemical characterization, quality assurance, and clinical research methodology.

9. Conclusions and Future Perspectives

The accumulated body of preclinical and emerging clinical evidence supports a substantive and mechanistically diverse anti-inflammatory potential for phytochemicals across multiple classes and disease contexts. Their capacity to simultaneously modulate NF-kB, MAPK, Nrf2, and NLRP3 pathways, regulate immune cell polarization, and attenuate oxidative stress positions them as multimodal agents well-suited to the complex, multifactorial pathophysiology of chronic inflammatory diseases. Importantly, their generally favourable safety profiles and widespread dietary availability confer intrinsic advantages over synthetic immunosuppressive agents for long-term disease management strategies.

Nonetheless, significant gaps remain before phytochemicals can be confidently integrated into mainstream clinical practice. The translation of compelling preclinical findings into meaningful clinical outcomes has been hampered by bioavailability limitations, formulation inconsistencies, and methodological weaknesses in clinical trial design. Future research must prioritize adequately powered, rigorously designed randomized controlled trials employing validated disease endpoints, standardized phytochemical preparations with documented bioavailability, and appropriate duration of follow-up. Pharmacogenomic studies are warranted to identify patient subpopulations most likely to benefit from phytochemical interventions, given the interindividual variability in metabolic enzyme activity and gut microbiome composition that influences phytochemical bioactivation [40].

The integration of advanced delivery technologies, including nano-formulation and targeted delivery systems, with the therapeutic potential of phytochemicals represents a particularly promising frontier. Combinatorial approaches that pair phytochemicals with conventional anti-inflammatory agents may enable dose-sparing strategies that preserve efficacy while reducing adverse effects. Regulatory harmonization and increased investment in phytochemical clinical research infrastructure are prerequisites for realizing the full therapeutic promise of these compounds. In synthesis, phytochemicals represent a scientifically credible, mechanistically rich, and clinically underexploited resource for addressing the global burden of chronic inflammatory disease.

Table 2: Summary of Advantages, Limitations, and Clinical Considerations in Phytochemical Use for Chronic Inflammatory Diseases

Domain	Key Observations	Clinical Implications
Therapeutic Advantages	Multi-target anti-inflammatory activity; favourable short-term safety profile; cost-effectiveness relative to biologics; dietary accessibility	Potential for long-term adjunctive use; broad applicability across inflammatory disease subtypes
Bioavailability	Most phytochemicals exhibit poor aqueous solubility and rapid phase II metabolism, limiting systemic exposure	Advanced formulation required; dose standardization critical for trial validity
Clinical Evidence Quality	Predominantly small, short-duration RCTs with heterogeneous endpoints; risk of publication bias	Larger, adequately powered trials with validated clinical endpoints are urgently needed
Safety and Drug Interactions	Generally safe at dietary doses; high-dose use may inhibit CYP450 enzymes and interact with anticoagulants, immunosuppressants	Comprehensive pharmacovigilance needed; caution in polypharmacy settings
Standardization	Variable phytochemical content across botanical preparations; batch-to-batch inconsistency	Regulatory frameworks for standardization of herbal preparations must be enforced globally
Regulatory Status	Classified as dietary supplements in many jurisdictions; limited approval as pharmaceuticals	Distinct regulatory pathways for botanical drugs needed to incentivize clinical development
Novel Delivery Technologies	PLGA nanoparticles, lipid carriers, cyclodextrin complexes improve bioavailability significantly	Clinical translation of advanced formulations underway; further safety data required

References

1. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, *et al*. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32.
2. World Health Organization. Noncommunicable diseases: key facts. Geneva: WHO; 2023.
3. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47(Suppl 2):S78–87.
4. Smolen JS, Landewé RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, *et al*. EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):685–99.
5. Listing J, Strangfeld A, Kary S, Rau R, von Hinüber U, Stoyanova-Scholz M, *et al*. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–12.
6. Tiwari R, Latheef SK, Ahmed I, Iqbal HM, Bule MH, Dhama K, *et al*. Herbal immunomodulators – a remedial panacea for designing and developing effective drugs and medicines: current scenario and future prospects. Curr Drug Metab. 2018;19(3):264–301.
7. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428–35.
8. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.
9. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38. Science. 2002;298(5600):1911–2.
10. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–89.
11. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126–67.
12. Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep. 2009;26(8):1001–43.
13. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47.
14. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–8.

15. Yao J, Kong W, Jiang J. Learning from berberine: treating chronic diseases through multiple targets. Sci China Life Sci. 2015;58(9):854–9.
16. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa. Altern Med Rev. 2009;14(2):141–53.
17. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim). 2010;343(9):489–99.
18. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci. 2008;65(19):2979–99.
19. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96(3):229–45.
20. Jiang W, Li M, He F, Bie Q, Wang W. Quercetin inhibits NLRP3 inflammasome activation with protection against diabetic cardiomyopathy. Mol Cell Endocrinol. 2021;520:111109.
21. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food Chem Toxicol. 1999;37(9–10):973–9.
22. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, *et al*. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109–22.
23. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57(9):1510–28.
24. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.
25. Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of Curcuma longa versus Zingiber officinale rhizomes in rat adjuvant-induced arthritis. Inflammation. 2011;34(4):291–301.
26. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.
27. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.
28. Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC. Therapeutic applications of curcumin nanoformulations. AAPS J. 2015;17(6):1341–56.
29. Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM. Therapeutic effects of turmeric or curcumin extract on pain and function for individuals with knee osteoarthritis: a systematic review. BMJ Open Sport Exerc Med. 2021;7(1):e000935.
30. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32(7):537–41.
31. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672–92.
32. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, *et al*. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660–5.
33. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytomedicine in the prevention of coronary artery disease and hypertension: overview of evidence and challenges. Chin Med. 2013;8:24.
34. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel). 2019;11(5):640.
35. Guri A, Corredig M. Bioactives at the interface of food and pharmaceuticals. J Agric Food Chem. 2012;60(28):6829–34.
36. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1000.
37. Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE. Americans' views on the use and regulation of dietary supplements. Arch Intern Med. 2001;161(6):805–10.
38. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670–95.
39. Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, *et al*. Best practice in research – overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020;246:112230.
40. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45.